Cardiogen Research Overview (also known as Cardiac peptide bioregulator, Khavinson heart peptide, Tetrapeptide Ala-Glu-Asp-Arg)
A cardiac-focused peptide studied for its influence on myocardial tissue stability, vascular tone regulation, and cardiac resilience under physical or age-related stress. Research interest includes endurance protocols and cardiovascular longevity applications.
What Is Cardiogen?
Cardiogen is a tetrapeptide bioregulator developed by Professor Vladimir Khavinson targeting cardiac muscle tissue (myocardium). It is one of the organ-specific peptide bioregulators in the Khavinson system, designed to restore normal functional activity to aging or damaged cardiomyocytes by acting as an epigenetic regulator of cardiac gene expression.
Target Tissue and Aging
The heart undergoes significant age-related changes: cardiomyocyte hypertrophy, increased fibrosis, reduced mitochondrial efficiency, and declining responsiveness to calcium signaling. These changes manifest as reduced cardiac reserve, decreased exercise tolerance, and increased vulnerability to ischemic events. Cardiogen is designed to counteract these aging-related deteriorations at the cellular level.
Research Applications
Animal studies have demonstrated improved cardiac contractility parameters, reduced fibrosis markers, and enhanced recovery from experimental ischemia in aged animals treated with Cardiogen. It is sometimes used alongside Ventfort (vascular bioregulator) in cardiovascular anti-aging protocols.
Quick Reference
| Literature-Reported Dose Range | 1–2 mg per injection |
| Literature-Reported Frequency | Once daily |
| Sites Reported in Studies | SubQ: abdomen, thigh, or upper arm |
| Literature-Reported Cycle Length | 20–30 days per course |
| Literature-Reported Washout | 2–3 courses per year; minimum 2 months off, 2–3× per year |
| Storage | Injectable: 2-8°C after reconstitution. Oral capsules: room temperature |
| Timing | AM or PM, consistent daily timing |
Research Indications
Cardiovascular
Cardiac Tissue Support
Preclinical models suggest cardiomyocyte proliferation stimulation and apoptosis suppression through p53 downregulation
Post-Injury Remodeling
Coronary artery ligation mouse models suggest reduced necrotic zones and improved survival outcomes
Chronic Heart Conditions
Russian clinical practice uses Cardiogen in treatment protocols for coronary heart disease, hypertension, and heart failure
Cellular Health
Cytoskeletal Protein Upregulation
Enhances expression of actin, vimentin, and tubulin 2-5x in fibroblasts, supporting cellular structural integrity
Nuclear Matrix Support
Increases lamin A and lamin C expression 2-3x, supporting nuclear architecture and gene regulation
Anti-Apoptotic Effects
Suppresses p53 protein expression in cardiomyocytes, reducing programmed cell death in cardiac tissue
Anti-Aging
Geroprotective Potential
Part of Khavinson bioregulator protocols targeting age-related cardiovascular decline through gene expression modulation
Age-Related Tissue Regeneration
Stimulates cardiac cell proliferation in both young and aged tissue cultures, maintaining regenerative capacity
Bioregulatory Peptide Therapy
Used in comprehensive Russian longevity protocols alongside organ-specific bioregulators
Research Protocols
As reported in cited literature and research-community logs (see Research Citations below) — not a personal dosing recommendation.
| Research Application | Dose | Frequency | Route |
|---|
| Standard Protocol | 1–2 mg daily | Once daily | SubQ |
Peptide Interactions
Theoretical synergy based on complementary mechanisms - Cardiogen supports cardiac tissue while BPC-157 promotes healing in gut and soft tissues. No published combination studies exist.
Theoretical synergy based on complementary mechanisms - TB-500 promotes blood vessel formation and broad tissue repair while Cardiogen provides heart-specific support. No published combination studies exist.
Complementary Khavinson bioregulators targeting different organ systems. Pinealon supports neuroprotection while Cardiogen targets cardiac tissue. Routinely combined in Russian longevity protocols.
Fellow Khavinson bioregulator targeting cartilage and connective tissue. Different tissue specificity allows combination without overlap. Used together in comprehensive anti-aging protocols.
Thymosin Alpha-1 supports immune modulation while Cardiogen targets cardiac tissue. Different mechanisms with no known interactions. May complement each other in recovery protocols.
Theoretical synergy through complementary pathways. Epitalon activates telomerase and regulates pineal function while Cardiogen supports cardiac tissue maintenance. Combined in Russian geroprotective protocols but no published combination studies exist.
Russian clinical practice uses Cardiogen alongside conventional treatments for heart conditions. Monitor cardiovascular parameters when combining with existing cardiac medications.
Both affect tissue proliferation pathways. Monitor for excessive fibroblast activation or unexpected tissue changes when combining growth-promoting compounds.
Reported Research Timeline
01Week 1–2 (reported in cited studies): no significant observable changes expected
02Week 2–4 (reported in cited studies): preclinical research suggests cellular-level cardiac tissue effects
03Month 1 (oral) (reported in cited studies): complete course; effects are cumulative per Russian protocols
04Long-term (reported in cited studies): benefits are theoretical, based on animal and in vitro data only
Safety Notes
Included for harm-reduction awareness only, in the event this compound is encountered outside its labeled research use. Inclusion here does not imply RUO Codes endorses, recommends, or instructs human use.
Not approved for human use by any regulatory agency (FDA, EMA)
All published research is preclinical - based on in vitro and animal studies only
Russian pharmaceutical capsule form available as dietary supplement in CIS countries
Side effects are reported as rare in Russian clinical experience when properly sourced
Not recommended during active cancer due to fibroblast proliferative effects
Not Recommended in pregnancy and lactation due to absence of safety data
Can be combined with conventional cardiovascular medications per Russian protocols
Seek Medical Attention If:
Unusual cardiovascular symptoms (chest pain, palpitations, shortness of breath)
Signs of allergic reaction (rash, swelling, difficulty breathing)
Persistent injection site reactions or inflammation
Digestive upset that persists beyond initial days (oral route)
Any unexpected or concerning symptoms - consult healthcare provider immediately
Quality Indicators
Verified Marker
White Lyophilized Powder
Pure Cardiogen appears as white to off-white lyophilized powder or cake
Verified Marker
Clear Reconstituted Solution
Properly reconstituted solution should be crystal clear with no particles
Verified Marker
Certificate of Analysis
Should include HPLC purity verification (>97%), sequence confirmation (AEDR), and mass spec data
Acceptable Range
Research Use Only
Cardiogen is not FDA approved - ensure proper research context
Quality Concern
Discolored or Cloudy Solution
Yellow, brown, or cloudy solution indicates degradation - do not use
Research Citations
- Tetrapeptide H-Ala-Glu-Asp-Arg-OH stimulates expression of cytoskeletal and nuclear matrix proteins
Khavinson, V.Kh., Lin'kova, N.S., Polyakova, V.O., Kvetnoy, I.M., Benberin, V.V., D'yakonov, M.M., Titkov, Yu.S., 2012, Bulletin of Experimental Biology and Medicine - The effect of the amino acids and cardiogen on the development of myocard tissue culture from young and old rats
Chalisova, N.I., Lesniak, V.V., Balykina, N.A., Urt'eva, S.A., Urt'eva, T.A., Sukhonos, Yu.A., Zhekalov, A.N., 2009, Advances in Gerontology - Tumor-modifying effect of cardiogen peptide on M-1 sarcoma in senescent rats
Levdik, N.V., Knyazkin, I.V., 2009, Bulletin of Experimental Biology and Medicine - The tissue-specific effect of synthetic peptides-biologic regulators in organotypic tissues culture in young and old rats
Zakutskii, A.N., Chalisova, N.I., Ryzhak, G.A., Aniskina, A.I., Filippov, S.V., Zeziulin, P.N., 2006, Advances in Gerontology - Peptidergic regulation of the expression of signal factors of fibroblast differentiation in the human prostate gland in cell aging
Kheifets, O.V., Polyakova, V.O., Kvetnoy, I.M., 2010, Advances in Gerontology - Peptides and aging
Khavinson, V.Kh., 2002, Neuroendocrinology Letters - Prevalence and prognostic value of autonomic neuropathy assessed by Sudoscan® in transthyretin wild-type cardiac amyloidosis
Kharoubi M, Roche F, Bézard M, 2021, ESC Heart Fail - Natural history and impact of treatment with tafamidis on major cardiovascular outcome-free survival time in a cohort of patients with transthyretin amyloidosis
Bézard M, Kharoubi M, Galat A, 2021, Eur J Heart Fail - Prognostic Value of N-Terminal Pro-Brain Natriuretic Peptide and High-Sensitivity Troponin T Levels in the Natural History of Transthyretin Amyloid Cardiomyopathy and Their Evolution after Tafamidis Treatment
Oghina S, Josse C, Bézard M, 2021, J Clin Med
Research Focus
Cardiac protection, Heart tissue restoration, Anti-aging, Cardiomyocyte function, Cardiovascular health
Verified Vendors Carrying Cardiogen
Frequently Asked Questions
What should researchers watch for with Cardiogen?
Included for harm-reduction awareness only, in the event this compound is encountered outside its labeled research use. Inclusion here does not imply RUO Codes endorses, recommends, or instructs human use.
What should researchers expect over time with Cardiogen?
Week 1–2 (reported in cited studies): no significant observable changes expected
How is Cardiogen typically administered in research?
As reported in cited literature and research-community logs (see Research Citations below) — not a personal dosing recommendation.
Browse all peptides in the Encyclopedia →